A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by stimulating the mother’s immune system to produce protective antibodies, which are then passed to the developing baby through the placenta. This mother-derived protection offers newborns with instant defence from the point of delivery, exactly when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence indicating that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85% protection when vaccinated 4 weeks before birth
- Maternal antibodies passed through the placenta protect newborns from birth
- Protection possible with 2-week gap before premature birth
- Vaccination in third trimester still offers meaningful infant protection
Persuasive evidence from the latest research
The effectiveness of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation undertaken in England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that half-year window, providing strong and reliable evidence of the vaccine’s actual performance. The study’s results have been supported by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The scale of this research provides healthcare professionals and prospective parents with assurance in the vaccine’s proven efficacy across diverse populations and circumstances.
The results present a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This stark contrast underscores the vaccine’s critical role in reducing the risk of serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research analysed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection levels and hospital admissions. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology assessed practical outcomes rather than laboratory-based settings, providing tangible evidence of how the vaccine performs when delivered across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and the dangers
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed adequately. Parents often witness their babies struggling visibly, their chests rising whilst they try to pull sufficient oxygen into their weakened respiratory system. Whilst most infants recover with palliative treatment, a small but significant number die from RSV-related complications annually, making prevention through vaccination a vital health service imperative for defending the most vulnerable and youngest individuals in the population.
- RSV triggers lung inflammation, leading to serious respiratory problems in infants
- Half of all infants catch the virus during their first few months alive
- Symptoms range from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV annually
- A small number of babies die from RSV complications annually in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme commenced in 2024, health officials have emphasised the value of pregnant women getting their jab at the optimal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns benefit from the maximum immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery offers nearly 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to enhance the antibodies passed to their babies through the placenta.
The guidance from public health bodies stays clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have attained higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to increase awareness and access to the jab. These regional differences demonstrate variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics demonstrates consistently strong protection regardless of geographical location.
- NHS trusts deploying diverse outreach initiatives to reach pregnant women
- Inconsistencies across regions in vaccination coverage levels throughout England require targeted improvement
- Local healthcare systems adapting programmes to meet local requirements and situations
Real-world impact and parent viewpoints
The vaccine’s impressive effectiveness delivers concrete gains for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the rollout of this preventative solution, the 80% drop in admissions means thousands of infants spared from critical disease. Parents no more face the troubling prospect of seeing their babies struggle for breath or difficulty feeding, symptoms that mark severe RSV infections. The vaccine has fundamentally shifted the terrain of neonatal breathing health, offering expectant mothers a preventative option to protect their youngest infants during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection resulted in profound brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s support of the jab highlights the transformative consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to pregnant women in their final trimester, converting what was once an unavoidable seasonal threat into a controllable health concern.